SEATTLE, Nov. 11, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design de novo protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present… Read More
AbCellera’s partner, Eli Lilly and Company, will supply the U.S. government with 300,000 doses of bamlanivimab for allocation to high-risk patients VANCOUVER, British Columbia, November 9, 2020 – AbCellera today… Read More
-U.S. Food & Drug Administration grants Priority Review for voclosporin and sets PDUFA date of January 22, 2021 – – Cash, cash equivalents and investments totaled approximately $421 million at… Read More
– NL-201 enhances activity of checkpoint inhibitors and tumor-targeting antibodies and increases immune cell stimulation – SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) — Neoleukin Therapeutics, Inc., “Neoleukin” (NASDAQ:NLTX), a biopharmaceutical company… Read More
For example, a BC college project is to find a practical method for calculating the total thermal resistance of a greenhouse. Algorithms are acquired to assess heat gain from sunlight… Read More
